Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health
Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital.
Topics: Medicine, Pharmaceuticals
-
-
Sigrid Therapeutics secures US market approval for SiPore® technology following successful SHINE prediabetes study
Sigrid Therapeutics (Sigrid) today announced that it has secured U.S. marketing approval for its patented SiPore® technology, following the successful SHINE study, the largest study of its kind in prediabetes.
-
Sigrid Therapeutics surpasses 50% patient recruitment in its clinical trial, SHINE, evaluating SiPore21® for sustainable diabetes and obesity control
Sigrid Therapeutics announced today that the company has recruited over 50% of patients in SHINE, a clinical trial evaluating SiPore21® for the treatment of elevated glucose levels.
-
First patient treated in Sigrid Therapeutics' clinical trial SHINE of the medical device SiPore21[®]
Sigrid Therapeutics is pleased to announce the start of the SHINE clinical trial for SiPore21® – an innovative medical device designed for long-term maintenance of blood sugar and weight control.
-
Sigrid Therapeutics' silica-based biomaterial SiPore15 [® ] granted US patent for treatment and prevention of obesity and overweight
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
-
Sigrid Therapeutics named by FierceMedTech as one of the "Fierce 15" companies in 2019 – the first Swedish winner ever
Sigrid Therapeutics announced today that the Company has been named by FierceMedTech as one of the 2019 “Fierce 15” companies, one of the most promising private medtech companies in the industry. This is the first time in its eight-year history that a Swedish company has been included on the list.
-
New study on mice published in Nanomedicine shows that Sigrid's medical device product SiPore15 prevents weight gain
Sigrid Therapeutics today announced the publication of a large study in mice in the peer-reviewed journal Nanomedicine. The study demonstrates enzyme-blocking effects of mesoporous silica particles (MSPs) administered into the intestine with effects on food efficiency and metabolic risk factors as a result.